Cue Health has been granted $481 million from the Department of Defense to manufacture and deploy millions of units of its rapid COVID-19 test.

The point-of-care molecular test detects viral RNA using a nasal swab sample from the lower part of the nose. The contract will go toward expanding the company’s production capacity and delivering 6 million tests by March of next year.

The test, which received an FDA Emergency Use Authorization for point-of-care use, delivers results in about 20 minutes using an automated cartridge reader and a mobile health app.